Lactose (India) Ltd.
Snapshot View

42.95 -1.35 ▼-3.1%

05 August 2021, 04:00:00 P.M.
Volume: 31,505

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.lactoseindia.com
Financial Indicators
Market Cap 48.15 Cr.
Earnings per share (EPS) -2.17 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 32.75 Trailing Twelve Months Ending 2021-03
Book Value / Share 30.68 Trailing Twelve Months Ending 2021-03
Price to Book Value 1.37 Calculated using Price: 42.10
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 1.14 Cr. 11,437,000 Shares
FaceValue 10
Company Profile

Lactose (India), a Toshniwal Group company, was incorporated in 1991, under the Companies Act, 1956. Its  plant in Vadodara, Gujarat was commissioned by Alfa Laval, Pune (which is a subsidary of Alfa Laval of Sweden) and was also given a ‘thumbs up’ by reputed dairy experts from the Netherlands in October 1991. Subsequently Alfa Laval, reputed dairy experts from Sweden and a joint commission from the Netherlands studied the plant and its working and confidently acknowledged the plant for its quality standards as well.

For ten years now, Lactose (India) Limited has stood for perfection, quality, constant innovation and complete dedication to their clients. With up to date technology, the company is one of India's leading producers of Edible and Pharmaceutical grade Lactose. Apart from this, the company also manufactures Dairy Whitener, Dairy Calcium, Whey Powder, Casein, Caseinate, Butter and Ghee.

The company still boasts of being the first company to manufacture Lactose in the Asian subcontinent. The company has since grown to be a leading player in the Lactose market and continues to supply consistent quality Lactose to several global giants in the pharmaceutical world. It commands a 40% overall market share and this makes the company the leading Lactose supplier in the country.

With its unparalled infrastructure of requisite equipment and dedicated work force, Lactose (India) has a state of the art manufacturing facility for contract manufacturing of pharmaceutical products.The latest in its diverse interests is the manufacturing of pharmaceutical formulations for Aventis Pharma (earlier-Hoechst Marion Roussel), for the purpose of domestic use and export to Russia.

The state of art manufacturing facilities for the manufacture of pharmacuetical formulations is in compliance with all international standards.The plant is approved under WHO-cGMP guidelines and also holds TUV certificate as an ISO 9001 : 2000 company.The manufacturing facilities include wet granulation,Fluid bed drying, compaction, blending and coating facilities with the latest technology equipments.The manufacturing facilities is well supported by its total in-house Quality Control set-up with latest Testing equipments and an upto date Microbiology Testing Laboratory. The facility is supported by an equally competent and FDA approved Manufacturing professionals.

Besides providing lactose for pharmaceutical giants, food,confectionary and dairy companies in India, the company's product also leaves Indian shores for the African continent, South East Asia, and some of its other neighbouring countries.

After achieving its ambitious goal of being the most successful and leading Lactose manufacturer and supplier in the country, the company is now venturing aggressively into exports of pharmaceuticals and related products.

Product range of the company includes:

  • Edible and Pharmaceutical grade Lactose
  • Dairy Whitener
  • Dairy Calcium
  • Whey Powder
  • Casein
  • Caseinate
  • Butter and Ghee.

Awards & Achievements:

  • TUV Certificate
  • An ISO 9001:2000 Certified company

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-3.05%
1 Week
+5.27%
1 Month
+34.43%
3 Month
+51.77%
6 Month
+80.84%
1 Year
+76.75%
2 Year
+129.68%
5 Year
-45.08%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 5.53 7.14 0.18 3.25 15.69 11.95 -4.59 2.20 0.21
Return on Capital Employed (%) 9.71 9.25 3.69 7.55 14.75 14.78 4.08 9.13 7.88
Return on Assets (%) 2.05 2.35 0.05 0.71 3.44 3.30 -1.59 0.88 0.09

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 13 15 15 16 20 27 32 34 34
Non Curr. Liab. 10 15 30 44 37 31 38 35 38
Curr. Liab. 13 17 16 20 26 27 13 12 11
Minority Int.
Equity & Liab. 36 47 60 80 83 85 83 82 83
Non Curr. Assets 17 27 47 67 66 68 66 64 64
Curr. Assets 19 20 13 13 17 17 17 18 20
Misc. Exp. not W/O
Total Assets 36 47 60 80 83 85 83 82 83

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 40 47 22 24 34 36 31 41 40
Other Income 0 1 1 0 1 1 1 0 0
Total Income 40 47 23 24 36 37 32 41 40
Total Expenditure -37 -44 -21 -19 -24 -24 -25 -31 -31
PBIDT 3 4 2 5 12 12 6 10 10
Interest -1 -1 -1 -3 -4 -4 -5 -5 -6
Depreciation -2 -2 -2 -2 -3 -3 -4 -4 -4
Taxation 0 0 0 0 -1 -2 1 0 0
Exceptional Items 2
PAT 1 1 0 1 3 3 -1 1 0

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. -3 14 7 13 1 8 0 5 8
Cash Fr. Inv. -3 -14 -21 -23 3 -5 -2 -2 -3
Cash Fr. Finan. 6 1 13 10 -5 -3 4 -5 -4
Net Change 0 1 -1 -1 0 0 3 -2 1
Cash & Cash Eqvt 0 1 1 0 0 0 3 1 2

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 42.90 42.90 42.90 42.90 42.90 42.90 42.90 49.13 49.13
Public 57.10 57.10 57.10 57.10 57.10 57.10 57.10 50.87 50.87
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 60.09 60.61 3.94 3.94 60.61 60.61 47.15 47.15

Announcements View Details

Wed, 04 Aug 2021
Board Meeting Intimation for Approval Of Un-Audited Financial Results Of The Company For The First Quarter Ended 30Th June 2021.
LACTOSE (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2021 inter alia to consider and approve 1. Un-audited Financial Results along with the Limited Review Report issued by the Statutory Auditors of the Company for the first quarter ended 30th June 2021.

2. Any other business with the permission of chair
Tue, 20 Jul 2021
Half Yearly Disclosure On Related Party Transaction
In Compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements)
(Amendments) Regulations 2018 we hereby submit the attached note on Related Party Transactions
on Standalone basis drawn in accordance with applicable accounting standards.
Wed, 14 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
This is to certify that the details of securities dematerialized during the quarter ended 30th June 2021 as required under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 have been furnished to BSE Limited where the shares of the Lactose (India) Limited are listed. The letter confirming this from our Registrar and Share Transfer Agent - BigShare Services Private Limited dated 03rd July 2021 is enclosed for your reference.

Technical Scans View Details

Thu, 05 Aug 2021
High Delivery Percentage High Delivery Percentage
Higher Delivery Quantity Higher Delivery Quantity
Higher Delivery Quantity and Percentage Higher Delivery Quantity and Percentage
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 188,551.74 785.85 +0.0%
Divi's Laboratories Ltd. 130,702.13 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. 79,575.04 4,783.30 +0.2%
Cipla Ltd. 76,243.85 945.20 +0.6%
Cadila Healthcare Ltd. 59,868.47 584.80 -0.5%
Piramal Enterprises Ltd. 59,065.41 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. 58,599.44 4,075.50 +0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.41 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 65.87 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.80 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 31.70 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.06 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 44.33 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 389.73 4,075.50 +0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.94 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 14.06 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.45 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 4.17 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.61 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1.73 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.75 4,075.50 +0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 0.10 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,075.50 +0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 14.13 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,075.50 +0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 32.07 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 17.85 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,075.50 +0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,075.50 +0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,075.50 +0.2%